Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3730 - Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study

Date

10 Oct 2016

Session

Poster display

Presenters

Anne-Claire Hardy-Bessard

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

A. Hardy-Bessard1, F. Brocard2, M. Leheurteur3, A. Melis4, J. Dauba5, A. Lortholary6, B. You7, E. Guardiola8, J. Grenier9, J. Martin-Babau10, J. Meunier11, P. Follana12, A. Savoye13, A. Mercier-Blas14, A. Marti15, R. Despax16, N. Barbier17, N. Gane18, P. Ardisson19, C. Segura-Djezzar20

Author affiliations

  • 1 Oncologie Médicale, Centre CARIO - HPCA, 22190 - Plerin-sur-Mer/FR
  • 2 Oncologie Médicale, ORACLE - Centre d'Oncologie de Gentilly, Nancy/FR
  • 3 Oncologie Médicale, Centre Henri Becquerel, Rouen/FR
  • 4 Oncologie Médicale, Hôpital Privé Sainte-Marie, Chalon-sur-Saône/FR
  • 5 Oncologie Médicale, Hôpital de Mont-de-Marsan, Mont de Marsan/FR
  • 6 Oncologie, Centre Catherine de Sienne, Nantes/FR
  • 7 Oncologie Médicale, Centre Hospitalier Lyon Sud, Pierre Bénite/FR
  • 8 Oncologie Médicale, CH de la Dracénie-Draguignan, Draguignan/FR
  • 9 Cancérologie Clinique, Institut Ste Catherine, Avignon/FR
  • 10 Institut De Cancérologie Et D'hématologie, C.H.U. Brest - Hôpital Morvan, Brest/FR
  • 11 Oncologie Médicale, C.H.R. Orleans - La Source, Orleans/FR
  • 12 Oncologie Médicale, Centre Antoine Lacassagne, Nice/FR
  • 13 Service Rubis - Oncologie Médicale, Institut Jean Godinot, Reims/FR
  • 14 Oncologie Médicale, Centre Hospitalier Privé de Saint-Grégoire, Saint-Grégoire/FR
  • 15 Service Oncologie, CH Auxerre, Auxerre/FR
  • 16 Oncologie - Hématologie, Clinique Pasteur - ONCOSUD, Toulouse/FR
  • 17 Oncologie Médicale, Centre Catalan d'Oncologie Clinique St. Pierre, Perpignan/FR
  • 18 Service De Biostatistique, Arcagy-Gineco, Paris/FR
  • 19 Service De Chimiothérapie, Clinique de la Sauvegarde, Lyon/FR
  • 20 Oncologie Médicale, Centre Francois Baclesse, Caen/FR
More

Resources

Abstract 3730

Background

Phase III combination of chemotherapy with BEV versus chemotherapy alone in first line MBC showed a benefit in favour of the combination in terms of PFS. Moreover, paclitaxel + BEV is a standard of care in Europe, and the main toxicity is sensory neuropathy (23.5 % of grade >= 3). The efficacy of E is well established in MBC pre-treated with taxanes and anthracyclines with a favourable safety profile. Therefore, our group initiated a study to assess the efficacy and safety of E + BEV combination in first-line MBC.

Methods

In this prospective, open-label, phase II study, patients with histologically confirmed HER2-negative MBC received as initial chemotherapy E every 3 weeks 1.23 mg/m2 on day 1 and day 8 for 6 cycles or more with BEV 15 mg/kg on day 1, until progression. The primary end point was non-progression rate at 1 year. Secondary end points were progression free survival (PFS) and safety.

Results

Of the 62 patients enrolled, 61 received the treatment. Median age was 59, 16% were triple negative, 30% had 3 metastatic sites or more. 71% of patients received prior chemotherapy, as adjuvant or neo-adjuvant treatment and 36% received hormonotherapy for MBC before enrolment. Median number of E cycles was 6 and 9 for BEV. The non-progression rate at 1 year was 32% (95% CI: 20%-43%), overall response rate (ORR) was 46%, and PFS was 8.3 months (95%CI: 7-9.6 months). Grade 3 or 4 neutropenia was observed in 26% patients only. Grade 3 HTA and thrombosis were observed in 39% and 8% of patients respectively. Grade 3 or 4 neuropathy occurred in 11% of patients. Other non-haematological adverse events were mild in severity.

Conclusions

This trial shows that E plus BEV has antitumor activity similar to paclitaxel plus BEV as first line chemotherapy in MBC, with an acceptable safety profile, notably a lower rate of neuropathy than expected with paclitaxel. This combination might be beneficial for patients with HER2-negative MBC what should be confirmed by further comparative study.

Clinical trial identification

NCT01341407

Legal entity responsible for the study

ARCAGY-GINECO

Funding

Eisai

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings